We are live on ! Find out more
ABEO icon

Abeona Therapeutics

100 hedge funds and large institutions have $188M invested in Abeona Therapeutics in 2025 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 24 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

322% more call options, than puts

Call options by funds: $8.67M | Put options by funds: $2.06M

58% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 24

36% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 14

5% more funds holding

Funds holding: 95100 (+5)

1.17% more ownership

Funds ownership: 68.23%69.4% (+1.2%)

5% less capital invested

Capital invested by funds: $198M → $188M (-$10.3M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
100
Holders Change
+5
Holders Change %
+5.26%
% of All Funds
1.31%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
19
Increased
38
Reduced
24
Closed
14
Calls
$8.67M
Puts
$2.06M
Net Calls
+$6.62M
Net Calls Change
-$5.63M
Name Holding Trade Value Shares
Change
Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$1.7M +$1.18M +185,285 +135%
JP Morgan Chase
27
JP Morgan Chase
New York
$1.49M -$3.48M -548,873 -66%
Citadel Advisors
28
Citadel Advisors
Florida
$1.44M +$1.73M +273,446 New
NM
29
Newtyn Management
New York
$1.31M -$1.47M -231,344 -48%
Qube Research & Technologies (QRT)
30
Qube Research & Technologies (QRT)
United Kingdom
$1.19M +$1.22M +192,075 +568%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$1.13M +$10.5K +1,663 +0.8%
Los Angeles Capital Management
32
Los Angeles Capital Management
California
$1.1M -$383K -60,371 -23%
TI
33
Trexquant Investment
Connecticut
$939K +$321K +50,559 +40%
DC
34
Diametric Capital
Massachusetts
$915K +$221K +34,838 +25%
PAM
35
Panagora Asset Management
Massachusetts
$848K +$1.02M +160,557 New
Wellington Management Group
36
Wellington Management Group
Massachusetts
$797K -$150K -23,585 -14%
Charles Schwab
37
Charles Schwab
California
$705K -$5.02K -792 -0.6%
UBS Group
38
UBS Group
Switzerland
$677K +$71.6K +11,290 +10%
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
$667K +$802K +126,384 New
PAI
40
Palo Alto Investors
California
$575K
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$336K -$24.3K -3,832 -6%
KCM
42
Knoll Capital Management
Florida
$331K
Barclays
43
Barclays
United Kingdom
$329K -$89.5K -14,104 -18%
LPL Financial
44
LPL Financial
California
$315K +$4.5K +710 +1%
N
45
Nuveen
North Carolina
$299K
Group One Trading
46
Group One Trading
Illinois
$253K +$58K +9,141 +24%
PCM
47
Prelude Capital Management
New York
$253K -$39.4K -6,219 -11%
XT
48
XTX Topco
Cayman Islands
$208K +$250K +39,359 New
Prudential Financial
49
Prudential Financial
New Jersey
$197K +$237K +37,311 New
Deutsche Bank
50
Deutsche Bank
Germany
$196K

ABEO Hedge Fund Activity: Q3 2025 in Review

100 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q3 2025, worth a combined $188M — down 5.2% from $198M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ABEO positions and 14 closed out — a net gain of 5 holders — while 38 added to existing stakes and 24 trimmed.

The largest buyer was Cable Car Capital, opening a new position worth an estimated $3.81M. The largest seller was Western Standard LLC, cutting an estimated $5.34M.

  • 100 institutional investors held Abeona Therapeutics (ABEO) as of Q3 2025, up from 95 in Q2 2025.
  • Funds reported $188M of Abeona Therapeutics stock for Q3 2025, down 5.2% quarter-over-quarter.
  • 19 funds opened new Abeona Therapeutics positions in Q3 2025 and 14 closed out, a net change of +5 holders.
  • The largest Abeona Therapeutics buyer in Q3 2025 was Cable Car Capital, an estimated $3.81M added.
  • The largest Abeona Therapeutics seller in Q3 2025 was Western Standard LLC, an estimated $5.34M sold.

Based on aggregated 13F filings for Q3 2025.